{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T23:02:47Z","timestamp":1767135767634,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd008037.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T00:00:00Z","timestamp":1594857600000}}],"reference-count":124,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008037.pub4","type":"journal-article","created":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T21:51:57Z","timestamp":1594849917000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Matthew N","family":"Hurley","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas L","family":"Forrester","sequence":"additional","affiliation":[{"name":"Respiratory Medicine; University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology (COG); School of Medicine, University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,7,16]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ppul.20771","article-title":"Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis","volume":"43","author":"Abdulhamid","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0002|cit2","first-page":"348","article-title":"Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis","volume":"40 Suppl 28","author":"Abdulhamid","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0003|cit3","first-page":"A2843","article-title":"Low dose nitric oxide as adjunctive therapy to reduce antimicrobial tolerance of pseudomonas aeruginosa biofilms in the treatment of patients with cystic fibrosis: Report of a proof of concept clinical trial","volume":"189","author":"Cathie","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"A159","DOI":"10.1136\/archdischild-2014-306237.367","article-title":"RATNO-reducing antibiotic tolerance using nitric oxide in cystic fibrosis: Report of a proof of concept clinical trial","volume":"99","author":"Cathie","year":"2014","journal-title":"Archives of disease in childhood"},{"issue":"9","key":"10.1002\/14651858.CD008037.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.ymthe.2017.06.021","article-title":"Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis","volume":"25","author":"Howlin","year":"2017","journal-title":"Molecular Therapy"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0006|cit6","first-page":"272","article-title":"A phase 2, 16-week, randomized, double-blind, placebo-controlled study to assess safety, tolerability and efficacy of repeated doses of KB001-A in subjects infected with P. aeruginosa","volume":"50 Suppl 41","author":"Chmiel","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD008037.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jcf.2017.12.006","article-title":"KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa","volume":"17","author":"Jain","year":"2018","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0008|cit8","unstructured":"Study to evaluate the effect of KB001-A on time-to-need for antibiotic treatment (KB001-A) www.clinicaltrials.gov\/ct2\/show\/NCT01695343"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0009|cit9","first-page":"A1190","article-title":"A phase I\/II study of the anti-PcrV antibody KB001 in cystic fibrosis patients with pseudomonas aeruginosa","volume":"179","author":"Milla","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0010|cit10","first-page":"341","article-title":"A phase 1\/2 randomized, double-blind, placebo-controlled, single-dose, dose escalation study of KB001 in cystic fibrosis patients infected with pseudomonas aeruginosa","volume":"43 Suppl 31","author":"Milla","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0011|cit11","first-page":"341","article-title":"Anti-inflammatory effect of KB001, an anti-PCRV antibody fragment, in CF patients chronically infected with pseudomonas aeruginosa","volume":"44 Suppl 32","author":"Milla","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD008037.pub4-BIB0012|cit12","first-page":"A1845","article-title":"Modulating Pseudomonas aeruginosa chronic Inflammation with the anti-PcrV antibody KB001: Results of a pilot clinical and pharmacodynamic study In subjects with cystic fibrosis","volume":"181","author":"Milla","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"7","key":"10.1002\/14651858.CD008037.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ppul.22890","article-title":"Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection","volume":"49","author":"Milla","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0014|cit14","unstructured":"Dose escalation study of KB001 in cystic fibrosis patients infected with Pseudomonas aeruginosa Pseudomonas aeruginosa clinicaltrials.gov\/ct2\/show\/NCT00638365"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0015|cit15","first-page":"S 134","article-title":"Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months","volume":"145","author":"Engl","year":"1997","journal-title":"Monatsschrift fur Kinderheilkunde"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/thorax.56.1.48","article-title":"Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis","volume":"56","author":"Renner","year":"2001","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0017|cit17","unstructured":"Renner S Wojnarowski C Koller DY Rust P Elmadfa I Eichler I Patients with cystic fibrosis (CF) benefit from \u03b2-Carotene supplementation for 6 months 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany 1998 97"},{"issue":"Suppl 15","key":"10.1002\/14651858.CD008037.pub4-BIB0018|cit18","first-page":"314","article-title":"Patients with cystic fibrosis (CF) benefit from \u03b2-Carotene supplementation for 6 months","volume":"24","author":"Renner","year":"1997","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0019|cit19","first-page":"51","article-title":"Influence of an oral beta-carotene supplementation on the antioxidant status of patients with cystic fibrosis","volume":"23","author":"Rust","year":"1997","journal-title":"Atemwegs und Lungenkrankheiten"},{"issue":"2","key":"10.1002\/14651858.CD008037.pub4-BIB0020|cit20","first-page":"83","article-title":"Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis","volume":"68","author":"Rust","year":"1998","journal-title":"International Journal for Vitamin and Nutrition Research"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000012818","article-title":"Long term beta-carotene supplementation in patients with cystic fibrosis - effects on oxidative status and pulmonary function","volume":"44","author":"Rust","year":"2000","journal-title":"Annals of Nutrition and Metabolism"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0022|cit22","unstructured":"Safety and Tolerability of Inhaled Nitric Oxide in Patients with Cystic Fibrosis www.clinicaltrials.gov\/ct2\/show\/NCT00570349"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0023|cit23","first-page":"299","article-title":"Safety and antimicrobial effects of inhaled nitric oxide in CF: a pilot study","volume":"44 Suppl 32","author":"Sagel","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0024|cit24","unstructured":"Kabra SK Effect of zinc supplementation in children with cystic fibrosis ctri.nic.in\/Clinicaltrials\/pmaindet2.php?trialid=3508&EncHid=&userName=zinc"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4187\/respcare.04038","article-title":"Zinc supplementation for one year among children with cystic fibrosis does not decrease pulmonary infection","volume":"61","author":"Sharma","year":"2016","journal-title":"Respiratory Care"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD008037.pub4-BIB0026|cit26","first-page":"337","article-title":"Quorum sensing molecules in sputum and plasma as biomarkers in patients with CF and chronic pseudomonas aeruginosa","volume":"43","author":"Smyth","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 31","key":"10.1002\/14651858.CD008037.pub4-BIB0027|cit27","first-page":"336","article-title":"A randomized controlled trial of macerated garlic oil in patients with CF and chronic pseudomonas aeruginosa","volume":"43","author":"Smyth","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0028|cit28","unstructured":"Smyth A The Garlic Against Pseudomonas (GAP) study www.isrctn.com\/ISRCTN21133397 10.1186\/ISRCTN21133397"},{"issue":"4","key":"10.1002\/14651858.CD008037.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/ppul.21193","article-title":"Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis - a pilot randomised controlled trial","volume":"45","author":"Smyth","year":"2010","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.metabol.2017.04.009","article-title":"Corrigendum to \"Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: a pilot randomized study of high-dose vitamin D3 administration\"","volume":"74","author":"Alvarez","year":"2017","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.metabol.2017.02.006","article-title":"Plasma metabolomics in adults with cystic fibrosis during a pulmonary exacerbation: a pilot randomized study of high-dose vitamin D3 administration","volume":"70","author":"Alvarez","year":"2017","journal-title":"Metabolism: Clinical and Experimental"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0032|cit32","first-page":"418","article-title":"Discovery-based, high resolution plasma metabolomics following a vitamin D3 intervention in adult patients with cystic fibrosis","volume":"49 Suppl 38","author":"Alvarez","year":"2014","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0033|cit33","first-page":"404","article-title":"Clinical responses to a novel vitamin D supplementation strategy in adult CF patients hospitalized for pulmonary exacerbations","volume":"46 Suppl 34","author":"Grossmann","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD008037.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4161\/derm.20332","article-title":"Pilot study of vitamin D supplementation in adults with cystic fibrosis pulmonary exacerbation: a randomized, controlled trial","volume":"4","author":"Grossmann","year":"2012","journal-title":"Dermato-endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD008037.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/ejcn.2012.82","article-title":"Impact of vitamin D supplementation on markers of inflammation in adults with cystic fibrosis hospitalized for a pulmonary exacerbation","volume":"66","author":"Grossmann","year":"2012","journal-title":"European Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0036|cit36","article-title":"High dose vitamin D is associated with decreased inflammatory markers and increased number of hospital-free days in adults with cystic fibrosis: A pilot study","volume":"26 Suppl","author":"Grossmann","year":"2012","journal-title":"FASEB journal"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0037|cit37","first-page":"409","article-title":"High dose vitamin D supplements in cystic fibrosis patients hospitalized for respiratory exacerbation","volume":"44 Suppl 32","author":"Kumari","year":"2009","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0038|cit38","unstructured":"Brown J Mellis CM Wood RE EDTA aerosol in pseudomonal lung infection 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England 1984 4.10"},{"issue":"8","key":"10.1002\/14651858.CD008037.pub4-BIB0039|cit39","first-page":"836","article-title":"Edetate sodium aerosol in Pseudomonas lung infection in cystic fibrosis","volume":"139","author":"Brown","year":"1985","journal-title":"American Journal of Diseases of Children"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0040|cit40","first-page":"353, Abstract n","article-title":"Effect of proton pump inhibitors on cystic fibrosis (CF) pulmonary exacerbations in adults [abstract]","volume":"47 Suppl 35","author":"DiMango","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1471-2466-14-21","article-title":"Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis","volume":"14","author":"Dimango","year":"2014","journal-title":"BMC Pulmonary Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jcf.2006.05.002","article-title":"Safety assessment of inhaled xylitol in subjects with cystic fibrosis","volume":"6","author":"Durairaj","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0043|cit43","first-page":"288","article-title":"Glutamine supplementation for cystic fibrosis - a randomised controlled trial","volume":"46 Suppl 34","author":"Forrester","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ppul.23370","article-title":"Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial","volume":"51","author":"Forrester","year":"2015","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3945\/ajcn.112.034207","article-title":"Oral magnesium supplementation in children with cystic fibrosis improves clinical and functional variables: a double-blind, randomized, placebo-controlled crossover trial","volume":"96","author":"Gontijo-Amaral","year":"2012","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jcf.2012.12.008","article-title":"A randomized placebo controlled study on the effects of L-arginine inhalation in patients with cystic fibrosis","volume":"46 Suppl 34","author":"Grasemann","year":"2011","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S1569-1993(11)60099-4","article-title":"Inhaled L-arginine in patients with cystic fibrosis - a randomized controlled trial","volume":"10 Suppl 1","author":"Grasemann","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD008037.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"371","DOI":"10.7150\/ijms.5.371","article-title":"Inhalation with fucose and galactose for treatment of Pseudomonas aeruginosa in cystic fibrosis patients","volume":"5","author":"Hauber","year":"2008","journal-title":"International Journal of Medical Sciences"},{"issue":"SH1","key":"10.1002\/14651858.CD008037.pub4-BIB0049|cit49","first-page":"S68","article-title":"Inhalation with Fucose and Galactose a new therapeutic approach in adult cystic fibrosis patients with Pseudomonas aeruginosa-Infection","volume":"55","author":"Pforte","year":"2001","journal-title":"Pneumologie (Stuttgart, Germany)"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0050|cit50","first-page":"305","article-title":"An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled alginate oligosaccharide delivered as a dry powder and as a nebulised solution in cystic fibrosis patients","volume":"49 Suppl 38","author":"Hodges","year":"2014","journal-title":"Pediatric Pulmonology"},{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0022-3476(95)70089-7","article-title":"Single- and multiple-dose-response relationships of beta-carotene in cystic fibrosis [see comment]","volume":"127","author":"Homnick","year":"1995","journal-title":"Journal of Pediatrics"},{"issue":"6","key":"10.1002\/14651858.CD008037.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ppul.10290","article-title":"Oral administration of specific yolk antibodies (IgY) may prevent Pseudomonas aeruginosa infections in patients with cystic fibrosis: a phase I feasibility study","volume":"35","author":"Kollberg","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD008037.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/jmf.2006.214","article-title":"More than 10 years' continuous oral treatment with specific immunoglobulin Y for the prevention of Pseudomonas aeruginosa infections: a case report","volume":"10","author":"Nilsson","year":"2007","journal-title":"Journal of Medicinal Food"},{"issue":"9","key":"10.1002\/14651858.CD008037.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ppul.20875","article-title":"Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients","volume":"43","author":"Nilsson","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD008037.pub4-BIB0055|cit55","first-page":"343","article-title":"Anti-pseudomonas IGY ready for phase III","volume":"45","author":"Kollberg","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008037.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1569-1993(11)60110-0","article-title":"Phase III study (IMPACTT) on anti-pseudomonas IgY","volume":"10","author":"Larsson","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(19)30190-0","article-title":"Clinical study to evaluate an anti-Pseudomonas aeruginosa IgY gargling solution (EUDRACT 2011-000801-39)","volume":"18","author":"Schuster","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"8","key":"10.1002\/14651858.CD008037.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.medmal.2008.06.023","article-title":"Phage therapy experience at the Eliava Institute","volume":"38","author":"Kutateladze","year":"2008","journal-title":"Medecine et Maladies Infectieuses"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/jmf.2008.0326","article-title":"Dietary supplementation with pressurized whey in patients with\u00a0cystic\u00a0fibrosis","volume":"13","author":"Lands","year":"2010","journal-title":"Journal of Medicinal Food"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1569-1993(10)60076-8","article-title":"Oral miglustat in homozygous F508del CF patients","volume":"9 Suppl 1","author":"Leonard","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jcf.2011.12.004","article-title":"A randomized placebo-controlled trial of miglustat in cystic fibrosis based on nasal potential difference","volume":"11","author":"Leonard","year":"2012","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0062|cit62","first-page":"355","article-title":"Pilot study of inhaled dry powder mannitol in young people with CF hospitalised with pulmonary exacerbation","volume":"47 Suppl 35","author":"Middleton","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0063|cit63","unstructured":"Middleton A Robinson P McKay K Selvadurai H Pilot study of inhaled dry powder mannitol in young people with cystic fibrosis hospitalised with pulmonary exacerbation Department of Respiratory Medicine, Children's Hospital at Westmead (www.thoracic.org.au) (accessed 21 Oct 2014) 2014"},{"issue":"2","key":"10.1002\/14651858.CD008037.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1183\/09031936.00137814","article-title":"A pilot study of inhaled dry-powder mannitol during cystic fibrosis-related pulmonary exacerbation [letter]","volume":"45","author":"Middleton","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jcf.2012.08.016","article-title":"Online Supplement to: \"Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis\"","volume":"13","author":"Moss","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jcf.2012.08.016","article-title":"Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis","volume":"12","author":"Moss","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0067|cit67","unstructured":"Single center, double-blind, randomized, placebo-controlled, two-period\/two-treatment crossover study investigating the effect of miglustat on the nasal potential difference in patients with cystic fibrosis homozygous for the F508del mutation clinicaltrials.gov\/ct2\/show\/NCT00742092"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0068|cit68","unstructured":"Phase III study to evaluate clinical efficacy and safety of avian polyclonal anti-Pseudomonas antibodies (IgY) in prevention of recurrence of Pseudomonas aeruginosa infection in cystic fibrosis patients clinicaltrials.gov\/ct2\/show\/NCT01455675"},{"issue":"2","key":"10.1002\/14651858.CD008037.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S1579-2129(10)70018-5","article-title":"Fatty acid supplements improve respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis","volume":"46","author":"Olveira","year":"2010","journal-title":"Archivos de Bronconeumologia"},{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.clnu.2005.10.011","article-title":"Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial","volume":"25","author":"Panchaud","year":"2006","journal-title":"Clinical Nutrition"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0071|cit71","first-page":"S88","article-title":"Dietary supplementation with omega-3 in cystic fibrosis (CF) patients","volume":"4 Suppl","author":"Panchaud","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0072|cit72","first-page":"104","article-title":"Zinc therapy in children with cystic fibrosis","volume":"27","author":"Safai-Kutti","year":"1991","journal-title":"Beitraege zur Infusionstherapie"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jcf.2010.09.005","article-title":"Effect of an antioxidant-rich multivitamin supplement in cystic fibrosis","volume":"10","author":"Sagel","year":"2011","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0074|cit74","first-page":"262","article-title":"Biomarkers of inflammation and oxidative stress in CF: implications for antiinflammatory drug development","volume":"51 Suppl 45","author":"Jain","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0075|cit75","first-page":"283","article-title":"Effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in CF","volume":"51 Suppl 45","author":"Sagel","year":"2016","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD008037.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1164\/rccm.201801-0105OC","article-title":"Effects of an antioxidant-enriched multivitamin in cystic fibrosis: randomized, controlled, multicenter trial","volume":"198","author":"Sagel","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD008037.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1177\/0884533615589991","article-title":"Changes in mineral micronutrient status during and after pulmonary exacerbation in adults with cystic fibrosis","volume":"30","author":"Lee","year":"2015","journal-title":"Nutrition in Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD008037.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/MAJ.0000000000000592","article-title":"Free 25-hydroxyvitamin D concentrations in cystic fibrosis","volume":"350","author":"Lee","year":"2015","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0079|cit79","unstructured":"Vitamin D for enhancing the immune system in cystic fibrosis clinicaltrials.gov\/show\/NCT01426256"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0080|cit80","first-page":"471","article-title":"High-dose vitamin D3 during acute pulmonary exacerbation in cystic fibrosis: a multi-center, double-blind, placebo-controlled trial","volume":"52 Suppl 47","author":"Tangpricha","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.conctc.2017.02.010","article-title":"The vitamin D for enhancing the immune system in cystic fibrosis (DISC) trial: rationale and design of a multi-center, double-blind, placebo-controlled trial of high dose bolus administration of vitamin D3 during acute pulmonary exacerbation of cystic fibrosis","volume":"6","author":"Tangpricha","year":"2017","journal-title":"Contemporary Clinical Trials Communications"},{"issue":"5","key":"10.1002\/14651858.CD008037.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/0891-5849(94)00203-V","article-title":"Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis","volume":"18","author":"Winklhofer-Roob","year":"1995","journal-title":"Free Radical Biology & Medicine"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1203\/00006450-199607000-00022","article-title":"Neutrophil elastase\/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation","volume":"40","author":"Winklhofer-Roob","year":"1996","journal-title":"Pediatric Research"},{"issue":"10","key":"10.1002\/14651858.CD008037.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/j.1651-2227.1995.tb13512.x","article-title":"Response to oral beta-carotene supplementation in patients with cystic fibrosis: a 16-month follow-up study.[erratum appears in Acta Paediatr 1996 Jan;85(1):124]","volume":"84","author":"Winklhofer-Roob","journal-title":"Acta Paediatrica"},{"issue":"2","key":"10.1002\/14651858.CD008037.pub4-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0022-3476(89)80804-2","article-title":"Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis","volume":"114","author":"Winnie","year":"1989","journal-title":"Journal of Pediatrics"},{"issue":"S2","key":"10.1002\/14651858.CD008037.pub4-BIB0086|cit86","first-page":"260","article-title":"Care-CF-1 trial: cysteamine, an oral adjunct to standard of care interventions in CF infectious exacerbations","volume":"53","author":"Devereux","year":"2018","journal-title":"Pediatric Pulmonology"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD008037.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S1569-1993(19)30191-2","article-title":"Evaluating appropriate PROMs in CARE-CF-1 trial: lynovex (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacerbations","volume":"18","author":"Devereux","year":"2019","journal-title":"Journal of Cystic Fibrosis"},{"issue":"12","key":"10.1002\/14651858.CD008037.pub4-BIB0088|cit88","first-page":"jrms.mui.ac.ir\/","article-title":"Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis","volume":"17","author":"Boskabady","year":"2012","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0089|cit89","unstructured":"Khorasani EN Mansouri F Effect of zinc supplementation on respiratory infections in children with cystic fibrosis Proceedings of European Respiratory Society Annual Congress; 2009; Sept 12-16; Vienna, Austria 2009 722s"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0090|cit90","first-page":"299","article-title":"EDTA combined with nebulised tobramycin improves bacterial clearance and lung function in cystic fibrosis patients with chronic pseudomonas aeruginosa infection","volume":"54","author":"Puvvadi","year":"2019","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0091|cit91","unstructured":"A phase IIb study of OligoG in subjects with cystic fibrosis colonized with Burkholderia spp www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2014-002125-35-DE"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0092|cit92","unstructured":"A study of oligog in cystic fibrosis subjects with burkholderia spp. infection clinicaltrials.gov\/show\/NCT02453789"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0093|cit93","first-page":"328","article-title":"Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP","volume":"50 Suppl 41","author":"Rye","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"S60, Abstract n","DOI":"10.1016\/S1569-1993(16)30275-2","article-title":"Standardised cultivation-independent methods to understand the effect of OligoG on Burkholderia and microbial diversity in the CF lung during a clinical trial","volume":"15 Suppl 1","author":"Weiser","year":"2016","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0095|cit95","first-page":"332","article-title":"Microbiota analysis of samples from a randomized double-blind, placebo-controlled cross-over study of inhaled alginate oligosaccharide (oligog) in cystic fibrosis individuals using aztreonam due to chronic colonization with burkholderia SPP","volume":"51","author":"Weiser","year":"2016","journal-title":"Pediatric pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1569-1993(17)30425-3","article-title":"Application of microbiota analysis to phase IIb trials of inhaled alginate oligosaccharide (Oligo G) in cystic fibrosis patients","volume":"16 Suppl 1","author":"Weiser","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0097|cit97","unstructured":"A cross-over study of OligoG in subjects with cystic fibrosis clinicaltrials.gov\/ct2\/show\/NCT01465529"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"S58, Abstract n","DOI":"10.1016\/S1569-1993(14)60182-X","article-title":"A first-in-patient clinical trial demonstrates that inhaled alginate oligosaccharide (OligoG) is well tolerated in cystic fibrosis (CF) patients [abstract]","volume":"13 Suppl 2","author":"Walshaw","year":"2014","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0099|cit99","unstructured":"Aerosolized hypertonic xylitol versus hypertonic saline in cystic fibrosis (CF) subjects clinicaltrials.gov\/ct2\/show\/NCT00928135"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0100|cit100","first-page":"150","article-title":"Oligo G: a novel mucolytic from basic science to clinical trials","volume":"52 Suppl 47","author":"Davies","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0101|cit101","first-page":"305","article-title":"A first in class mucus conditioning drug-effect of an inhaled alginate oligosaccharide (oligo-g) on mucus clearance in subjects with cystic fibrosis","volume":"52 Suppl 47","author":"Donaldson","year":"2017","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1569-1993(17)30158-3","article-title":"A double blind, randomised, placebo-controlled cross over study of inhaled alginate oligosaccharide (OligoG) administered for 28 days in subjects with cystic fibrosis","volume":"16 Suppl 1","author":"Pressler","year":"2017","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0103|cit103","first-page":"271","article-title":"A double-blind, randomised, placebo-controlled cross-over study of inhaled alginate oligosaccharide (OLIGOG) administered for 28 days in subjects with cystic fibrosis","volume":"51 Suppl","author":"Pressler","year":"2016","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0104|cit104","unstructured":"Pressler T A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis (SMR-2984) Clinicaltrials.gov"},{"issue":"4","key":"10.1002\/14651858.CD008037.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/153537020623100402","article-title":"Bacteriophage endolysins as a novel class of antibacterial agents","volume":"231","author":"Borysowski","year":"2006","journal-title":"Experimental Biology and Medicine"},{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1183\/09031936.00099506","article-title":"Cystic fibrosis mortality and survival in the UK: 1947-2003","volume":"29","author":"Dodge","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"1","key":"10.1002\/14651858.CD008037.pub4-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/ijc.25008","article-title":"Beta-carotene supplementation and cancer risk: a systematic review and meta-analysis of randomized controlled trials","volume":"127","author":"Druesne-Pecollo","year":"2010","journal-title":"International Journal of Cancer"},{"issue":"4","key":"10.1002\/14651858.CD008037.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"issue":"7414","key":"10.1002\/14651858.CD008037.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0110|cit110","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"12","key":"10.1002\/14651858.CD008037.pub4-BIB0111|cit111","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.chembiol.2008.10.009","article-title":"Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB","volume":"15","author":"Johansson","year":"2008","journal-title":"Chemistry and Biology"},{"issue":"4","key":"10.1002\/14651858.CD008037.pub4-BIB0112|cit112","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004197.pub4","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","author":"Langton-Hewer","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD008037.pub4-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ppul.10401","article-title":"Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center","volume":"37","author":"Lee","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD008037.pub4-BIB0114|cit114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009650.pub4","article-title":"Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis","author":"Lo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008037.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD008037.pub4-BIB0116|cit116","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009876.pub4","article-title":"Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis","author":"Regan","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0117|cit117","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"3","key":"10.1002\/14651858.CD008037.pub4-BIB0118|cit118","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1067\/mpd.2001.117288","article-title":"Defining a pulmonary exacerbation in cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD008037.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0022-3476(98)70344-0","article-title":"The diagnosis of cystic fibrosis: A consensus statement","volume":"132","author":"Rosenstein","year":"1998","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0120|cit120","unstructured":"UK Cystic Fibrosis Trust Infection Control Group Pseudomonas aeruginosa infection in people with cystic fibrosis: Suggestions for prevention and infection control Report of the UK Cystic Fibrosis Infection Control Group 2004"},{"key":"10.1002\/14651858.CD008037.pub4-BIB0121|cit121","unstructured":"UK Cystic FIbrosis Antibiotic Working Group Antibiotic Treatment for Cystic Fibrosis - 3rd Edition Cystic Fibrosis Trust 2009"},{"issue":"13","key":"10.1002\/14651858.CD008037.pub4-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1128\/JB.00486-08","article-title":"Cell-cell communication in bacteria: united we stand","volume":"190","author":"Bodman","year":"2008","journal-title":"Journal of Bacteriology"},{"issue":"10","key":"10.1002\/14651858.CD008037.pub4-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008037.pub2","article-title":"Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis","author":"Hurley","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD008037.pub4-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008037.pub3","article-title":"Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis","author":"Hurley","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T03:18:03Z","timestamp":1636687083000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008037.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,7,16]]},"references-count":124,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008037.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,16]]}}}